Kimberley M. Heinhuis

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio).

Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio).

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 28, 2023

Detection and localization of early- and late-stage cancers using platelet RNA.

Detection and localization of early- and late-stage cancers using platelet RNA.

Journal: Cancer cell

Published: December 06, 2021

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 08, 2021

PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.

PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.

Journal: BMJ open

Published: September 11, 2020

Neoadjuvant Systemic Treatment of Primary Angiosarcoma.

Neoadjuvant Systemic Treatment of Primary Angiosarcoma.

Journal: Cancers

Published: July 10, 2020

A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute.

A cost analysis study of the implementation of fixed-dosing of monoclonal antibodies in the Netherlands Cancer Institute.

Journal: International journal of clinical pharmacy

Published: May 27, 2020

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 20, 2020

RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics.

RNA-Sequencing of Tumor-Educated Platelets, a Novel Biomarker for Blood-Based Sarcoma Diagnostics.

Journal: Cancers

Published: April 07, 2020

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.

Journal: JAMA oncology

Published: November 08, 2019

Follow up survey for implementation of fixed-dosing of monoclonal antibodies.

Follow up survey for implementation of fixed-dosing of monoclonal antibodies.

Journal: International journal of clinical pharmacy

Published: July 16, 2019

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 05, 2019

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

Journal: PloS one

Published: July 15, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026